Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer
Published in: Breast Cancer 2/2018

01-03-2018 | Original Article

Passive smoking, NAT2 polymorphism, and breast cancer risk in Israeli Arab women: a case–control study

Authors: Z. Regev-Avraham, O. Baron-Epel, S. K. Hammond, L. Keinan-Boker

Published in: Breast Cancer | Issue 2/2018

Login to get access

Abstract

Background

The effect of passive smoking (PS) on breast cancer (BC) is controversial, and may be modified by polymorphism of the N-Acetyl-transferase (NAT) 2 enzyme which is involved in tobacco carcinogen metabolism. We aimed to evaluate the relationship between PS and BC by NAT2 variants in Arab–Israeli women, a unique population with low active smoking rates, and high exposure to PS.

Methods

A population-based case-control study was carried out on non-smoking 137 prevalent breast cancer patients and 274 population-based controls, aged 30–70 years. Data on past and current PS, sociodemographic, and other characteristics were retrieved through interviews, and buccal smears were provided for NAT2 analyses. Logistic regression models adjusting for potential confounders assessed the odds ratios (ORs) and 95% confidence intervals (95% CI) of the association between PS and BC.

Results

Ever PS was associated with increased BC risk: OR = 2.22, 95% CI 1.28–3.87. Higher lifetime PS exposure was associated with higher BC risk: Compared to never exposed women, women exposed to PS most of their lives had a threefold higher BC risk (OR = 3.16, 95% CI 1.70–5.87, P trend < 0.001). NAT2 polymorphism did not modify these associations.

Conclusions

PS exposure in non-smoking Israeli Arab women is significantly associated with increased risk for BC, potentially allowing for specific intervention; NAT2 polymorphism does not modify this association.
Literature
1.
Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from: http://​globocan.​iarc.​fr. Accessed 21 June 2017.
2.
3.
Beaber EF, Buist DS, Barlow WE, Malone KE, Reed SD, Li CI. Recent oral contraceptive use by formulation and breast cancer risk among women 20–49 years of age. Cancer. 2014;74(15):4078–89.
4.
Zbuk K, Anand SS. Declining incidence of breast cancer after decreased use of hormone-replacement therapy: magnitude and time lags in different countries. J Epidemiol Community Health. 2012;66(1):1–7.CrossRefPubMed
5.
Pettersson A, Graff RE, Ursin G, Santos-Silva ID, McCormack V, Baglietto L et al. Mammographic density phenotypes and risk of breast cancer: a meta-analysis. J Natl Cancer Inst 2014;106(5).
6.
Boyle P, Levin B. International Agency for Research on Cancer. IARC monographs on the evaluation of carcinogenic risks to humans’ tobacco smoke and in voluntary smoking. 83 vol. Lyon: World Health Organization; 2008.
7.
Johnson KC. Accumulating evidence on passive and active smoking and breast cancer risk. Int J Cancer. 2005;117(4):619–28.CrossRefPubMed
8.
Johnson KC, Miller AB, Collishaw NE, Pamer JR, Hammond SK, Salom AG, et al. Active smoking and secondhand smoke increase breast cancer risk: the report of the Canadian Expert Panel on Tobacco Smoke and Breast Cancer Risk. Tob Control. 2011;20:e2.CrossRefPubMed
9.
10.
11.
Chen C, Huang YB, Liu XB, Gao Y, Dai HJ, Song FJ, et al. Active and second hand smoking with breast cancer risk for Chinese females: a systematic review and meta-analysis. Chin J Cancer. 2014;33(6):306–16.CrossRefPubMedPubMedCentral
12.
Dossus L, Boutron-Ruault MC, Kaaks R, Gram IT, Vilier A, Fervers B, et al. Active and passive cigarette smoking and breast cancer risk: results from the EPIC cohort. Int J Cancer. 2014;134(8):1871–88.CrossRefPubMed
13.
Gao CM, Ding JH, Li SP, Liu YT, Qian Y, Chang J, et al. Active and second hand smoking, and alcohol drinking and breast cancer risk in Chinese women. Asian Pac J Cancer Prev. 2013;14(2):993–6.CrossRefPubMed
14.
Anderson LN, Cotterchio M, Mirea L, Ozcelik H, Kreiger N. Passive cigarette smoke exposure during various periods of life, genetic variants, and breast cancer risk among never smokers. Am J Epidemiol. 2012;175(4):289–301.CrossRefPubMed
15.
Boukouvala S, Fakis G. Arylamine N-acetyltransferases: what we learn from genes and genomes. Drug Metab Rev. 2005;37:511–64.CrossRefPubMed
16.
Cascorbi I, Drakoulis N, Brockmoller J, Maurer A, Sperling K, Roots I. Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. Am J Hum Genet. 1995;57:581–92.CrossRefPubMedPubMedCentral
17.
Baumgartner K, Schlierf T, Yang D, Doll M, Hein D. N-acetyltransferase 2 genotype modification of active cigarette smoking on breast cancer risk among hispanic and non-hispanic white women. Toxicol Sci. 2009;112(1):211–20.CrossRefPubMedPubMedCentral
18.
Alberg AJ, Daudt A, Huang HY, Hoffman SC, Comstock GW, Helzlsouer KJ, et al. N-acetyltransferase 2 (NAT2) genotypes, cigarette smoking, and the risk of breast cancer. Cancer Detect Prev. 2004;28:187–93.CrossRefPubMed
19.
20.
Lissowska J, Brinton LA, Zatonski W, Blair A, Bardin-Mikolajczak A, Peplonska B, et al. Tobacco smoking, NAT2 acetylation genotype and breast cancer risk. Int J Cancer. 2006;119:1961–9.CrossRefPubMed
21.
Conlon MS, Johnson KC, Bewick MA, Lafrenie RM, Donner A. Smoking (active and passive), N-acetyltransferase 2, and risk of breast cancer. Cancer Epidemiol. 2010;34(2):142–9.CrossRefPubMed
22.
Ambrosone CB, Kropp S, Yang J, Yao S, Shields PG, Chang-Claude J. Cigarette smoking, N-acetyltransferase 2 genotypes, and breast cancer risk: pooled analysis and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2008;17(1):15–26.CrossRefPubMed
23.
24.
Ben Noach M, Steinberg DM, Rier DA, Goldsmith R, Shimony T, Rosen LJ. Ethnic differences in patterns of secondhand smoke exposure among adolescents in Israel. Nicotine Tob Res. 2012;14(6):648–56.CrossRefPubMed
25.
Baron-Epel O, Keinan-Boker L, Weinstein R, Shohat T. Persistent high rates of smoking among Israeli Arab males with concomitant. Isr Med Assoc J. 2010;12(12):732–7.PubMed
26.
27.
Hammond SK, Leaderer BP. A diffusion monitor to measure exposure to passive smoking. Environ Sci Technol. 1987;21(5):494–7.CrossRefPubMed
28.
Caka FM, Eatough DJ, Lewis EA, Tang H, Hammond SK, Leaderer BP, et al. An intercomparison of sampling techniques for nicotine in indoor environments. Environ Sci Technol. 1990;24(8):1196–203.CrossRef
29.
Brian P, Leaderer BP, Hammond SK. Evaluation of vapor-phase nicotine and respirable suspended particle mass as markers for environmental tobacco smoke. Environ Sci Technol. 1991;25(4):770–7.CrossRef
30.
31.
García-Closas M, Malats N, Silverman D, Docemeci M, Kogevinas M, Hein DW, et al. NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. Lancet. 2005;366(9486):649–59.CrossRefPubMedPubMedCentral
32.
33.
Sadri G, Mahjub H. Passive or active smoking, which is more relevant to breast cancer. Saudi Med J. 2007;28(2):254–8.PubMed
34.
Chen Z, Shao J, Gao X, Li X. Effect of passive smoking on female breast cancer in China: A meta-analysis. Asia Pac J Public Health. 2013;27(2):NP58–64.CrossRefPubMed
35.
Miller MD, Marty MA, Broadwin R, Jhonson KC, Samon AG, Winder B, et al. The association between exposure to environmental tobacco smoke and breast cancer: a review by the California Environmental Protection Agency. Prev Med. 2007;44(2):93–106.CrossRefPubMed
36.
Li Q, Hsia J, Yang G. Prevalence of smoking in China in 2010. N Engl J Med. 2011;364(25):2469–70.CrossRefPubMed
37.
Ahern T, Lash T, Egan K, Baron J. Lifetime tobacco smoke exposure and breast cancer incidence. Cancer Causes Control. 2009;20(10):1837–44.CrossRefPubMed
38.
Okasha M, McCarron P, Gunnell D, Smith GD. Exposures in childhood, adolescence and early adulthood and breast cancer risk: a systematic review of the literature. Breast Cancer Res Treat. 2003;78(2):223–76.CrossRefPubMed
39.
Liu L, Wu K, Lin X, Yin Y, Zheng X, Tang X, et al. Passive smoking and other factors at different periods of life and breast cancer risk in Chinese women who have never smoked—a case–control study in Chongqing, People’s Republic of China. Asian Pac J Cancer Prev. 2000;1(2):131–7.PubMed
40.
Biro FM, Deardorff J. Identifying opportunities for cancer prevention during preadolescence and adolescence: puberty as a window of susceptibility. J Adolesc Health. 2013;52(5 Suppl):S15–20.CrossRefPubMedPubMedCentral
41.
Reynolds P, Goldberg D, Hurley S, Nelson DO, Largent J, Henderson KD, et al. Passive smoking and risk of breast cancer in the California Teachers Study. Cancer Epidemiol Biomarkers Prev. 2009;18(12):3389–98.CrossRefPubMedPubMedCentral
42.
Cox DG, Dostal L, Hunter DJ, Le Marchand L, Hoover R, Ziegler RG. N-acetyltransferase 2 polymorphisms, tobacco smoking, and breast cancer risk in the breast and prostate cancer cohort consortium. Am J Epidemiol. 2011;174(11):1316–22.CrossRefPubMedPubMedCentral
43.
Zhang J, Qiu LX, Wang ZH, Wang JL, He SS, Hu XC. NAT2 polymorphisms combining with smoking associated with breast cancer susceptibility: a meta-analysis. Breast Cancer Res Treat. 2010;123(3):877–83.CrossRefPubMed
44.
Metadata
Title
Passive smoking, NAT2 polymorphism, and breast cancer risk in Israeli Arab women: a case–control study
Authors
Z. Regev-Avraham
O. Baron-Epel
S. K. Hammond
L. Keinan-Boker
Publication date
01-03-2018
Publisher
Springer Japan
Published in
Breast Cancer / Issue 2/2018
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-017-0809-5

Other articles of this Issue 2/2018

Breast Cancer 2/2018 Go to the issue

Original Article

Candidate miRNAs in human breast cancer biomarkers: a systematic review

Original Article

Risk factors for complications among breast cancer patients treated with post-mastectomy radiotherapy and immediate tissue-expander/permanent implant reconstruction: a retrospective cohort study

Original Article

Investigating the therapeutic potential and mechanism of curcumin in breast cancer based on RNA sequencing and bioinformatics analysis

Original Article

Clinicopathological study of a dimorphic variant of breast carcinoma

Original Article

Schisandrin A reverses doxorubicin-resistant human breast cancer cell line by the inhibition of P65 and Stat3 phosphorylation

Original Article

UBAP2L silencing inhibits cell proliferation and G2/M phase transition in breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits